MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with an initial focus on industrial safety applications in South America’s mining sector. The company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation in large enterprise environments.
Leyton brings extensive experience in national drug policy and workplace safety. He helped design and implement Chile’s ‘Zero Tolerance’ alcohol-impaired driving law as part of the country’s alcohol prevention framework and played a role in establishing Chile’s roadside drug testing program introduced in 2019. His appointment reflects MindBio’s strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is closely tied to workplace safety and compliance requirements.
The biotechnology company is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. MindBio is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction, and law enforcement.
This move is significant for industrial safety, particularly in mining operations where impairment can lead to catastrophic accidents. By deploying voice-based detection, companies can non-invasively and quickly screen workers for impairment, potentially reducing workplace incidents and improving compliance with safety regulations. The technology’s ability to detect both alcohol and drugs addresses a critical gap in current testing methods, which often require time-consuming blood or saliva tests.
For the mining industry in South America, where safety standards are increasingly stringent, MindBio’s platform offers a scalable solution that can be integrated into existing safety protocols. The appointment of Leyton, with his background in shaping Chile’s drug and alcohol policies, positions the company to navigate regulatory landscapes effectively and build trust with local authorities and enterprises.
The implications extend beyond mining to other high-risk sectors such as aviation and construction, where impairment detection can save lives and reduce liability. As the technology matures, its deployment could set new standards for workplace safety globally. MindBio’s focus on AI-driven voice analysis also highlights the growing role of artificial intelligence in occupational health and safety, offering a cost-effective and accurate alternative to traditional testing.
For more information on MindBio Therapeutics, visit the company’s newsroom at https://ibn.fm/MBQIF. The full article can be viewed at https://ibn.fm/JBNVq.
